Department of Molecular Genetics, Weizmann Institute of Science, 234 Herzl str., 7610001, Rehovot, Israel.
Tata Institute of Fundamental Research, Mumbai, India.
Mol Psychiatry. 2021 Mar;26(3):725-735. doi: 10.1038/s41380-020-00936-8. Epub 2020 Nov 5.
In recent years, it has been revealed that Parkinson's disease pathology may begin to manifest in the gastrointestinal track at a much earlier time point than in the brain. This paradigm shift has been suggested following evidence in humans that has been reproduced in animal models. Since rodent models cannot recapitulate many of the human disease features, human induced pluripotent stem cells derived from Parkinson's patients have been used to generate brain organoids, greatly contributing to our understanding of the disease pathophysiology. To understand the multifaced aspects of Parkinson's disease, it may be desirable to expand the complexity of these models, to include different brain regions, vasculature, immune cells as well as additional diverse organ-specific organoids such as gut and intestine. Furthermore, the contribution of gut microbiota to disease progression cannot be underestimated. Recent biotechnological advances propose that such combinations may be feasible. Here we discuss how this need can be met and propose that additional brain diseases can benefit from this approach.
近年来,有研究表明,帕金森病的病理变化可能比大脑更早地在胃肠道中显现。这种范式转变的依据是在人类中发现的证据,并且在动物模型中得到了重现。由于啮齿动物模型无法再现许多人类疾病特征,因此已使用源自帕金森病患者的人诱导多能干细胞来生成脑类器官,这极大地促进了我们对疾病病理生理学的理解。为了了解帕金森病的多方面方面,可能需要扩大这些模型的复杂性,以包括不同的大脑区域、血管、免疫细胞以及其他不同的特定于器官的类器官,例如肠道。此外,肠道微生物群对疾病进展的贡献不可低估。最近的生物技术进步表明,这种组合可能是可行的。在这里,我们讨论如何满足这一需求,并提出其他脑部疾病也可以从中受益。